Showing 2621-2630 of 4067 results for "".
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://reachmd.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials.
- Researchers Trace a Form of Lupus Back to a Single Mutationhttps://reachmd.com/news/researchers-trace-a-form-of-lupus-back-to-a-single-mutation/2456896/In this cell, Toll-like receptor 7 was stained pink in order to analyse its amount and position under the microscope. The cell is healthy and the amount of Toll-like receptor is normal. The situation is different in the immune cells of lupus patients, whi
- Goldstein Selected to Help Lead Statewide Task Force Addressing Heart Disease and Strokehttps://reachmd.com/news/goldstein-selected-to-help-lead-statewide-task-force-addressing-heart-disease-and-stroke/2456852/LEXINGTON, Ky. (Jan. 12, 2024) — Larry Goldstein, M.D., chair of the
- Hypertension's Hidden Hand: Pressure-Driven Foam Cell Formation Revealed as Key Driver of Arterial Disease, Paving the Way for New Therapieshttps://reachmd.com/news/hypertensions-hidden-hand-pressure-driven-foam-cell-formation-revealed-as-key-driver-of-arterial-disease-paving-the-way-for-new-therapies/2456777/A new study in Advanced Science unlocks the secrets of how high blood pressure (hypertension) fuels the progression of arterial disease. Le
- Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Phase 3 Datahttps://reachmd.com/news/inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-phase-3-data/2487213/Key Takeaways Median forced vital capacity decline at week 52 was smaller with treprostinil than with placebo. Clinical worsening occurred in 31.8% versus 44.5%, with a hazard ratio of 0.67, and no significant difference was seen in time to IPF exacerb
- Comparative Efficacy of Single-Inhaler Triple Therapies in COPDhttps://reachmd.com/news/comparative-efficacy-of-single-inhaler-triple-therapies-in-copd/2486960/Key Takeaways Fluticasone furoate/vilanterol/umeclidinium was the regimen specifically reported as having significant trough FEV1 advantages in the network comparison. Fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium, a
- iS Clinical Launches New Eye Gel Highlighting Multimodal Periocular Carehttps://reachmd.com/news/is-clinical-launches-new-eye-gel-highlighting-multimodal-periocular-care/2486957/A new topical formulation targeting the periocular region is entering the aesthetics market, with iS Clinical announcing the launch of GeneXC Firming Eye Gel. The product is designed to address common concerns such as laxity, uneven tone, and dehydration in the delicate eye area. The formu
- SkinCeuticals Launches Future Mineral UV Defense SPF 50 for Daily and Post-Procedure Usehttps://reachmd.com/news/skinceuticals-launches-future-mineral-uv-defense-spf-50-for-daily-and-post-procedure-use/2486804/SkinCeuticals has introduced Future Mineral UV Defense SPF 50, a new mineral sunscreen designed to provide broad-spectrum UV protection while also addressing visible signs of skin aging, according to the company. The formulation combines 15% zinc oxide and 3% titanium dioxide and is intend
- Epicutis Reports 8-Week Clinical Findings for New Hydrobiome Serumhttps://reachmd.com/news/epicutis-reports-8-week-clinical-findings-for-new-hydrobiome-serum/2486634/Epicutis has introduced Hydrobiome Serum, a new professional skincare product positioned for redness, congestion, and barrier disruption. The formulation centers on TCP, a proprietary isoprenyl cysteine compound developed by Signum Biosciences, and is paired with sodium tocopheryl phosphate, a wa
- Revision Skincare Announces 2 Studies Evaluating 30% THD Ascorbate Serum for Skin Quality Outcomeshttps://reachmd.com/news/revision-skincare-announces-2-studies-evaluating-30-thd-ascorbate-serum-for-skin-quality-outcomes/2486573/Two peer-reviewed studies published in the Journal of Cosmetic Dermatology evaluated the cosmetic efficacy and tolerability of a high-strength vitamin C formulation containing 30% tetrahexyldecyl ascorbate (THD ascorbate) (C+ Correcting Complex 30%; Revision Skincare), Revision Skincare<